The phase II OPUS trial echoed these findings, with cetuximab augmenting the effectiveness of FOLFOX4 in KRAS wild-type patients.258 A meta-analysis of the CRYSTAL and OPUS trials underscored the significant survival advantage for KRAS wild-type patients receiving cetuximab plus chemotherapy over chemotherapy alone.259 Recently, the FDA approved the combination of encorafenib and cetuximab for BRAF^V600E mutant mCRC based on the BEACON CRC trial, which demonstrated a median OS benefit.260. This evidence concerns the gene BRAF and colorectal carcinoma.